These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Renal tolerance of iodinated low osmolality contrast agents. Clinical and experimental aspects]. Deray G; Dubois M; Bellin MF; Grellet J; Jacobs C J Radiol; 1990; 71(6-7):439-44. PubMed ID: 2254874 [TBL] [Abstract][Full Text] [Related]
8. Decision analysis to assess cost-effectiveness of low-osmolality contrast medium for intravenous urography. Calvo MV; Pilar del Val M; Mar Alvarez M; DomÃnguez-Gil A Am J Hosp Pharm; 1992 Mar; 49(3):577-84. PubMed ID: 1598930 [TBL] [Abstract][Full Text] [Related]
9. The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. Caro JJ; Trindade E; McGregor M AJR Am J Roentgenol; 1991 Apr; 156(4):825-32. PubMed ID: 1825900 [TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rudnick MR; Goldfarb S Rev Cardiovasc Med; 2003; 4 Suppl 5():S28-33. PubMed ID: 14668707 [TBL] [Abstract][Full Text] [Related]
11. Comparative safety of high-osmolality and low-osmolality radiographic contrast agents. Report of a multidisciplinary working group. Lawrence V; Matthai W; Hartmaier S Invest Radiol; 1992 Jan; 27(1):2-28. PubMed ID: 1733876 [No Abstract] [Full Text] [Related]
12. Fatal adverse event secondary to high osmolality contrast agent. Guharoy R; Medicis J; Lehmann D Vet Hum Toxicol; 1998 Oct; 40(5):285-7. PubMed ID: 9778765 [TBL] [Abstract][Full Text] [Related]